ENSTILAR calcipotriol (as monohydrate) 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g foam aerosol can Australia - English - Department of Health (Therapeutic Goods Administration)

enstilar calcipotriol (as monohydrate) 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g foam aerosol can

leo pharma pty ltd - calcipotriol, quantity: 20.5 microgram/g; betamethasone dipropionate, quantity: 264 microgram/g (equivalent: betamethasone, qty 205 microgram/g) - foam - excipient ingredients: polyoxypropylene-11 stearyl ether; liquid paraffin; dl-alpha-tocopherol; white soft paraffin; butane; methyl ether - enstilar is indicated for the topical treatment of psoriasis vulgaris in adults.

ENSTILAR- calcipotriene and betamethasone dipropionate aerosol, foam United States - English - NLM (National Library of Medicine)

enstilar- calcipotriene and betamethasone dipropionate aerosol, foam

leo pharma inc. - calcipotriene monohydrate (unii: s7499tyy6g) (calcipotriene - unii:143nq3779b), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - calcipotriene 50 ug in 1 g - enstilar® (calcipotriene and betamethasone dipropionate) foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. none. risk summary available data with enstilar foam are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. although there are no available data on use of the calcipotriene component in pregnant women, systemic exposure to calcipotriene after topical administration of enstilar foam is likely to be low [see clinical pharmacology (12.3)]. observational studies suggest an increased risk of having low birth weight infants with the maternal use of potent or super potent topical corticosteroids (see data). advise pregnant women that enstilar® foam may increase the potential risk of having a low birth weight infant and to use enstilar foam on the smallest area of skin and for the shortest duration possible. in animal reproduction studies, oral administration of calcipotriene to pregnant

ENSTILAR Israel - English - Ministry of Health

enstilar

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - cutaneous foam - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations - topical treatment of psoriasis vulgaris in adults

ENSTILAR Israel - English - Ministry of Health

enstilar

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - cutaneous foam - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations - topical treatment of psoriasis vulgaris in adults

Enstilar New Zealand - English - Medsafe (Medicines Safety Authority)

enstilar

leo pharma limited - betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone;  ; calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol - foam - active: betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone   calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol excipient: butane liquid paraffin methyl ether polyoxypropylene monostearyl ether tocoferols white soft paraffin - topical treatment of psoriasis vulgaris in adults.

Enstilar 50 micrograms/g + 0.5 mg/g cutaneous foam Ireland - English - HPRA (Health Products Regulatory Authority)

enstilar 50 micrograms/g + 0.5 mg/g cutaneous foam

leo pharma a/s - calcipotriol; betamethasone - cutaneous foam - 50 mcg/g + 0.5 milligram(s)/gram - other antipsoriatics for topical use; calcipotriol, combinations

Enstilar 50micrograms/g / 0.5 mg/g cutaneous foam United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

enstilar 50micrograms/g / 0.5 mg/g cutaneous foam

leo pharma - betamethasone dipropionate; calcipotriol monohydrate - cutaneous foam - 500microgram/1gram ; 50microgram/1gram

Enstilar 50 micrograms/0.5mg/g cutaneous foam. Malta - English - Medicines Authority

enstilar 50 micrograms/0.5mg/g cutaneous foam.

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - calcipotriol monohydrate, betamethasone dipropionate - cutaneous foam - calcipotriol monohydrate 50 µg/g betamethasone dipropionate 0.5 mg/g - antipsoriatics

Enstilar® (Calcipotriol 50 mcgg + Bethamethasone Dipropionate 0.5 mgg) Cutaneous Foam Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enstilarâ® (calcipotriol 50 mcgg + bethamethasone dipropionate 0.5 mgg) cutaneous foam

dksh malaysia sdn. bhd. - betamethasone dipropionate; calcipotriol monohydrate -

ENSTILAR AEROSOL, FOAM Canada - English - Health Canada

enstilar aerosol, foam

leo pharma inc - betamethasone (betamethasone dipropionate); calcipotriol (calcipotriol monohydrate) - aerosol, foam - 0.5mg; 50mcg - betamethasone (betamethasone dipropionate) 0.5mg; calcipotriol (calcipotriol monohydrate) 50mcg - anti-inflammatory agents